Drug
BF-200 ALA clinical trials
- studies test it
- 8
- open now
- 0
- in phase 3
- 4
- first study started
- 2006
How studies write it
Studies that test it under each name
Name
Studies by the year they started
8 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 3
- 4
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 3
Biofrontera Bioscience GmbH (5) · Joint Authority for Päijät-Häme Social and Health Care (3)
Often tested with
Tested in the same studies.
Methyl aminolevulinate (3) · Hexaminolevulinate hydrochloride (1)
Studies
Open first, then newest update. How each study uses BF-200 ALA is read from its arms, and is right about nine times in ten.
Testing it · 8
- Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)CompletedPhase 3Biofrontera Bioscience GmbHNCT01966120Written as BF-200 ALA gel
- Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic TherapyCompletedPhase 3Biofrontera Bioscience GmbHNCT02144077Written as BF-200 ALA
- Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MALActive, not recruitingPhase 1/2Joint Authority for Päijät-Häme Social and Health CareNCT02367547Written as Aminolevulinic Acid Nano Emulsion
- Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing CreamCompletedPhase 4Joint Authority for Päijät-Häme Social and Health CareNCT02685592Written as 5-aminolevulinic acid nanoemulsion
- Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic TherapyCompletedPhase 3Biofrontera Bioscience GmbHNCT02799069Written as BF-200 ALA
- Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.CompletedPhase 3Biofrontera Bioscience GmbHNCT02799082Written as BF-200 ALA
- A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic KeratosisCompletedPhase 2Biofrontera Bioscience GmbHNCT02799030Written as BF-200 ALA 1%
- Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL)CompletedPhase 4Joint Authority for Päijät-Häme Social and Health CareNCT01893203Written as BF-200 ALA cream